These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10632319)

  • 1. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
    Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
    Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
    Messinger Y; Yanishevski Y; Ek O; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
    Clin Cancer Res; 1998 Jan; 4(1):165-70. PubMed ID: 9516966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies.
    Chen CL; Levine A; Rao A; O'Neill K; Messinger Y; Myers DE; Goldman F; Hurvitz C; Casper JT; Uckun FM
    J Clin Pharmacol; 1999 Dec; 39(12):1248-55. PubMed ID: 10586390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
    Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
    Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells.
    Myers DE; Jun X; Waddick KG; Forsyth C; Chelstrom LM; Gunther RL; Tumer NE; Bolen J; Uckun FM
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9575-9. PubMed ID: 7568175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis.
    Waddick KG; Chae HP; Tuel-Ahlgren L; Jarvis LJ; Dibirdik I; Myers DE; Uckun FM
    Radiat Res; 1993 Dec; 136(3):313-9. PubMed ID: 7506428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
    Meany HJ; Seibel NL; Krailo M; Villaluna D; Chen Z; Gaynon P; Neglia JP; Park JR; Hutchinson R; Sato JK; Wells RJ; Woods WG; Reaman G
    J Immunother; 2015 Sep; 38(7):299-305. PubMed ID: 26261894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.
    Ek O; Yanishevski Y; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
    Leuk Lymphoma; 1998 Jul; 30(3-4):389-94. PubMed ID: 9713969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
    Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.
    Myers DE; Sicheneder A; Clementson D; Dvorak N; Venkatachalam T; Sev AR; Chandan-Langlie M; Uckun FM
    Leuk Lymphoma; 1998 Apr; 29(3-4):329-38. PubMed ID: 9684930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia.
    Herrera L; Bostrom B; Gore L; Sandler E; Lew G; Schlegel PG; Aquino V; Ghetie V; Vitetta ES; Schindler J
    J Pediatr Hematol Oncol; 2009 Dec; 31(12):936-41. PubMed ID: 19875969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
    Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
    Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases.
    Uckun FM; Evans WE; Forsyth CJ; Waddick KG; Ahlgren LT; Chelstrom LM; Burkhardt A; Bolen J; Myers DE
    Science; 1995 Feb; 267(5199):886-91. PubMed ID: 7531365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
    Weiss MA; Aliff TB; Tallman MS; Frankel SR; Kalaycio ME; Maslak PG; Jurcic JG; Scheinberg DA; Roma TE
    Cancer; 2002 Aug; 95(3):581-7. PubMed ID: 12209751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.